SPECTROLYSE® PAI-1（纤溶酶原激活剂抑制物P

INTENDED USE
SPECTROLYSE® PAI-1 is intended for the quantitative determination of Plasminogen Activator Inhibitor Type-1 (PAI-1) activity in human plasma. The test is for in vitro diagnostic use.

EXPLANATION OF THE TEST
Plasminogen Activator Inhibitor Type-1 (PAI-1) is a rapid, specific inhibitor of plasminogen activator in plasma. As a primary regulator of fibrinolysis, PAI-1 is found in a number of different tissues and cell types including macrophages and monocytes, hepatocytes, vascular endothelia cells, adipose tissue of the heart and lungs and platelets. The clinical interest in measuring PAI-1 in plasma is based on case studies in which levels of this serine protease inhibitor are associated with various thrombotic and fibrinolytic complications. Deficiency of PAI-1 activity is associated with bleeding disorders wherein the routine hemostatic screening tests are normal. An increased level of PAI-1 is a key factor in impaired fibrinolytic function and may be associated with thrombotic diseases.High levels of PAI-1 activity are found in patients suffering from myocardial infarction, hemolytic remic syndrome, and stroke.Levels of PAI-1 in the plasma of pregnant women are also correlated with gestational diabetes, reduced placental blood flow and preeclampsia.Patients with cirrhosis may also have elevated levels of PAI-1.